First-Ever, Nationwide, Multicenter, Prospective Study of Canine Splenic Hemangiosarcoma

, , ,

Cutting Edge Cancer Research in Veterinary Specialty Practice: Ethos Veterinary Health Completes First-Ever, Nationwide, Multicenter, Prospective Study of Canine Splenic Hemangiosarcoma

Woburn, Mass. — Jan. 15, 2019 — Ethos Veterinary Health (Ethos) has completed the patient accrual phase of their new Canine Hemangiosarcoma Molecular Profiling (CHAMP) study.

Hemangiosarcoma is one of the most malignant forms of cancer in dogs and CHAMP is the first nationwide, multicenter, prospective study of canine splenic hemangiosarcoma, which is a cancer of the blood vessels often affecting the spleen.

“Ethos is proud of this unprecedented milestone and of our investments in innovation that will improve outcomes for our patients,” said Ames Prentiss, CEO of Ethos Veterinary Health.

The clinical description of this population of dogs with splenic tumor rupture, a common diagnosis made on an emergency basis, is expected to be submitted for publication before the end of Q1 2019 by Dr. Sam Stewart, DACVECC and colleagues at Ethos.

“I expect the CHAMP study to change many misperceptions of hemangiosarcoma in the veterinary community, and ultimately help pet owners and veterinarians make better decisions regarding treatment,” said Sam Stewart, DVM, DACVECC, Science Commercialization Fellow at Ethos Veterinary Health.

The study also provided state-of-the-art care to dogs with splenic tumor rupture over a 12-month period and allowed for the collection samples for molecular analysis. CHAMP will result in a molecular characterization of genomic alterations in canine hemangiosarcoma which will help identify dogs with distinct prognoses and potentially life-saving molecularly-targeted therapies. Publication of these genomic data is expected in Q2 2019.

“When viewed from the perspective of a veterinarian trained to treat cancer – I am a veterinary Oncologist – the new genomic analysis of this highly aggressive cancer has already provided an opportunity for me to treat dogs differently,” said Chand Khanna, DVM, PhD, DACVIM (Onc), Chief Science Officer of Ethos Veterinary Health. “We are very excited to now launch clinical trials that will assess these new treatments and change outcomes for dogs with this very aggressive cancer.”

A critical component of this prospective study will be the molecular characterization of the disease recently completed through a collaboration of Ethos and The Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This Ethos-TGen collaboration allowed for the use of advanced next generation sequencing technology of tumor and blood samples collected from the CHAMP dogs.

Will Hendricks, Ph.D., Assistant Professor, Integrated Cancer Genomics Division of TGen, added: “The results of this collaboration between TGen and Ethos will bring needed evidence to the field of molecular and precision medicine. We are not only excited about the application of these data to dogs, but also to human patients with very similar cancers as part of a comparative approach to cancer biology and therapy, so-called comparative oncology.”

These new trials will open through Ethos practices in Q2 2019. In parallel, additional studies are ongoing to develop a molecular diagnostic to help define the prognosis of individual dogs and identify optimal molecularly derived treatments for each patient.

 

# # #

About Ethos Veterinary Health

Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members and collaboration. For more information, visit ethosvet.com.

About Ethos Discovery

Ethos Discovery is a 501(c)(3) non-profit incubator of scientific innovation that seeks to improve health outcomes in pets and humans with complex medical problems, including cancer. For more information, please visit ethosdiscovery.org.

About TGen, an affiliate of City of Hope

Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is affiliated with City of Hope, a world-renowned independent research and cancer and diabetes treatment center: www.cityofhope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes, and infectious diseases, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.

Contacts

Ethos Veterinary Health
Nadja Torling, Director of Marketing
ntorling@ethosvet.com

 

Ethos Veterinary Health LLC Recapitalization with Brown Brothers Harriman Capital Partners

, ,

Brown Brothers Harriman Completes Investment in Ethos Veterinary Health LLC

New York, NY, JANUARY 9, 2019BBH Capital Partners (“BBHCP”) announced today that it has completed a recapitalization of Ethos Veterinary Health LLC (“Ethos” or the “Company”). Headquartered in Woburn, Massachusetts, Ethos is one of the largest pure-play independent providers of specialty veterinary health services, including 24/7 emergency care, surgical procedures, radiology services and internal medicine. Ethos operates 21 specialty and emergency hospitals and employs over 300 doctors of veterinary medicine. In addition, Ethos provides a complementary suite of reference laboratory and compounding pharmacy services and has developed a well-regarded continuing education and training platform to support the ongoing professional development of its veterinarians and technicians.

Ethos has earned a national reputation among veterinary professionals for providing exceptional quality-of-care, world-class professional development as well as a veterinarian-first culture. After the recapitalization, Ethos remains majority owned by its founders and professionals in the veterinary industry under the leadership of CEO and Co-Founder Ames Prentiss and is well capitalized to further accelerate a growth strategy that will continue to focus on expanding existing hospitals, acquisitions and growth of the complementary suite of services.

[Read More]

About Ethos Veterinary Health

Ethos is a veterinary health company with 17 hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members, and collaboration. For more information, visit ethosvet.com.

About BBH Capital Partners

BBH Capital Partners (“BBHCP”), a private equity strategy of Brown Brothers Harriman & Co., provides friendly capital solutions to growth-oriented middle-market companies. Our flexible investment mandate gives us the ability to act as a control or non-control investor and to structure our investments as a combination of equity and subordinated debt securities as needed. BBHCP typically invests between $30 million and $125 million per platform investment, and our capital is used to support a variety of transactions, including management or leveraged buyouts, growth financings, recapitalizations (including dividend recapitalizations), buy-and-build strategies and acquisitions.

Contacts

Ethos Veterinary Health
Nadja Torling, Director of Marketing
ntorling@ethosvet.com

Western Reserve Partners Advises Ethos Veterinary Health

, ,

Western Reserve Partners Advises Ethos Veterinary Health in its Growth Equity Recapitalization

CLEVELAND, OH (December 18, 2018)Western Reserve Partners, a division of Citizens Capital Markets, Inc., is pleased to announce that it served as the exclusive financial advisor to Ethos Veterinary Health, LLC (“Ethos” or the “Company”) in its recapitalization by Brown Brothers Harriman Capital Partners (“BBHCP”). Through the recapitalization, Ethos remains independently owned by its veterinarian professionals and, under the leadership of founding CEO Ames Prentiss, is well capitalized to further accelerate its acquisition-focused growth strategy.

Headquartered in Woburn, Massachusetts, Ethos is a leading provider of specialty veterinary health services with over 300 doctors of veterinary medicine throughout the United States. The Company’s unique integrated clinical model includes 21 specialty & emergency hospitals and a suite of complementary reference laboratory, compounding pharmacy and SaaS-based training services. The Company, formed in 2015 through the merger of four veterinary hospital systems, has since acquired six additional hospital systems and also earned a national reputation among veterinary professionals for providing exceptional quality-of-care, world-class professional development and a veterinarian-first culture. Through this minority equity recapitalization with Brown Brothers Harriman, Ethos has provided liquidity to its owners, gained a partner with significant experience scaling multi-unit healthcare businesses and positioned itself for future organic and acquisitive growth.

[Read More]

About Western Reserve Partners

Western Reserve Partners, a division of Citizens Capital Markets, Inc., provides M&A, capital raising and other financial advisory services to middle market companies across a focused set of industry verticals. We deliver thoughtful advice, keen market insight and superior execution to our clients, both nationally and internationally, and our managing directors average nearly 30 years of experience and have directly executed more than 700 transactions throughout their careers.

Western Reserve Partners is a part of Citizens Financial Group, one of the oldest and largest financial institutions in the U.S. Also, as a member of Oaklins, the world’s most experienced mid-market M&A advisory organization, Western Reserve Partners has unparalleled access to global companies and investors.

Contacts

Ethos Veterinary Health
Nadja Torling, Director of Marketing
ntorling@ethosvet.com

Ethos Supports Initiative to Establish Standard Title and Scope of Practice for Veterinary Technicians

, ,

Woburn, Mass., August 24, 2018 –Ethos Veterinary Health (Ethos) has developed a position statement in support of NAVTA’s Veterinary Nurse Initiative (VNI). The initiative by the National Association of Veterinary Technicians in America is aimed at establishing a national credential for Registered Veterinary Nurses (RVN).

Ethos fully supports this work given its importance in improving patient care. “Ethos has a strong commitment to the continuous growth and development of our team members, and we believe the Veterinary Nurse Initiative provides a crucial guiding framework to help us achieve this goal,” said Patrick Welch, DVM, MBA, DACVO, Chief Knowledge Officer of Ethos Veterinary Health.“We are excited to take an active role in supporting NAVTA in their efforts around this initiative.”

The statement reads as follows:

Ethos Veterinary Health mission is to provide unsurpassed veterinary health care for patients and their human companions. We recognize the vital role that veterinary technicians play in the integrated veterinary healthcare team, and that this collaborative approach to care is essential to achieving this mission.

We support the goals of the Veterinary Nurse Initiative (VNI) to unite the profession with one standard title and scope of practice. The VNI will increase public awareness of the profession and elevate and align practice standards, leading to better patient care and consumer protection. These goals are consistent with our core values of collaboration, continuous development, innovation, quality, and teamwork. Ethos Veterinary Health is proud to support the Veterinary Nurse Initiative.

For more information about Ethos’s support of this initiative please contact Ed Carlson at ecarlson@ethosvet.com.

About Ethos Veterinary Health

Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members and collaboration.

Media Contact

Nadja Torling
720-722-3418
ntorling@ethosvet.com

The American College of Veterinary Internal Medicine and VetBloom Enter into Unique Partnership

,

WOBURN, Mass.–(BUSINESS WIRE)–The American College of Veterinary Internal Medicine (ACVIM) has entered into a partnership with VetBloom, the digital learning ecosystem from Ethos Veterinary Health (Ethos).

This multifaceted partnership will actualize development of a Virtual Learning Environment for ACVIM and its members and allow collaboration on the development of eLearning modules. In addition, VetBloom will develop an integrated online portal for tracking and reporting of data related to the Maintenance of Credential (MOC) program for ACVIM Diplomates, as well as for tracking of Resident Specialty training and credentials.

The aim of the partnership is to create an industry-leading platform for the ACVIM membership, as well as a tool to allow the ACVIM to externalize their expertise to the broader veterinary industry. Key aspects of the partnership include:

  • A fully branded ACVIM learning site with custom resources for members
  • Paperless, online, automated MOC and Resident Specialty Tracking
  • An ACVIM eCommerce portal for non-members
  • Ongoing, digital, access to ACVIM events
  • Access to curated education from VetBloom and other members of the VetBloom learning community

“I’m excited about this unique partnership,” said Patrick Welch, DVM, MBA, DACVO, Chief Knowledge Officer of Ethos Veterinary Health. “Both ACVIM and VetBloom bring rich and complementary knowledge and experience to the relationship, and this presents us with a synergistic opportunity to develop a learning ecosystem that creates tremendous benefit for a number of audiences.”

Veronica Muñoz, Chief Executive Officer of the ACVIM, added, “VetBloom is a trusted resource in the veterinary field. We look forward to combining VetBloom’s expertise in developing veterinary education with ACVIM’s subject matter expertise. Our partnership creates a best-in-class resource for our membership and the industry as a whole.”

The ACVIM and VetBloom teams will launch the platform following the 2018 ACVIM Forum, with additional functionality and content to be added throughout the remainder of the year.

About the ACVIM

Based in Greenwood Village, Colo., the American College of Veterinary Internal Medicine (ACVIM) is the certifying organization for veterinary specialists in cardiology, large animal internal medicine, neurology, oncology, and small animal internal medicine. With more than 2,850 members, the ACVIM is dedicated to improving the lives of animals and people through the education, training, and certification of specialists in veterinary internal medicine, discovery and dissemination of new medical knowledge, and increasing public awareness of advances in veterinary medical care. www.acvim.org

About VetBloom

VetBloom is an innovative learning ecosystem featuring the expertise of the finest veterinary professionals in the industry, along with cutting-edge, online instruction. Team members learn through direct and virtual instruction, interactive case-based scenarios and 3D simulations. VetBloom allows veterinary professionals to advance their skills from anywhere in the world. For more information visit vetbloom.com.

About Ethos Veterinary Health

Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members and collaboration. For more information, visit ethosvet.com.

Contacts

Ethos Veterinary Health
Media Contact:
Nadja Torling, Director of Marketing
ntorling@ethosvet.com
or
Aileen Holland, 303-231-9933
Aileen@acvim.org

LexaGene Announces Collaboration with Ethos Veterinary Health

,

BEVERLY, Mass., April 04, 2018 (GLOBE NEWSWIRE) — LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, announced today that it has entered into collaboration with Ethos Veterinary Health, a veterinary health company with hospitals across the U.S. that provide advanced medical care for pets. This partnership will provide canine urine samples to LexaGene for testing on the Company’s LX6 prototype for more effective, rapid and on-site pathogen detection. The samples have been previously characterized using conventional technologies (MALDI-TOF / mass spectrometry) at its reference laboratory.

“In the coming weeks, veterinarians at Ethos will send LexaGene clinical annotated samples for processing, which will allow our team to continue to fine-tune and perfect our pathogen detection prototype’s testing capabilities,” said Dr. Jack Regan, LexaGene CEO. “This process is vital as we improve sensitivity to different isolates. We expect this to be a long-lasting collaboration as we work together to bring the best product possible to the veterinary market.”

“We’ve recently performed a market assessment for LexaGene’s technology by interviewing many emergency and critical care veterinarians, and – coupled with an internal financial assessment of the cost of conventional testing versus LexaGene’s projected testing costs – the results argue strongly for adopting LexaGene’s technology once available,” added Dr. Chand Khanna, Chief Science Officer, Ethos Veterinary Health. “We look forward to providing samples to LexaGene so that we can help them bring this product to market quickly and efficiently, ultimately enabling veterinarians to provide better care for clients in the near future.”

To be added to the LexaGene email distribution list, please subscribe on the Company website here.

To view the LexaGene website, click here.

###

About LexaGene Holdings Inc.
LexaGene is a biotechnology company developing the very first fully automated pathogen detection platform that is open-access, the LX6.  The open-access feature will empower end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection.  End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The instrument is expected to offer excellent sensitivity, specificity, and breadth of pathogen detection.  The instrument will be able to process six samples at a time, in an on-demand fashion, returning results in about 1 hour.  The company expects to sell its technology in the food safety, veterinary diagnostics, water quality monitoring, and aquaculture pathogen surveillance markets.

About Ethos Veterinary Health
Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members and collaboration. For more information, visit ethosvet.com.

View Dr. Chand Khanna’s bio here.

 

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues — that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contacts
Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207
ckasunich@kcsa.comasingh@kcsa.com

LMU and Ethos Veterinary Health Collaborate on Research, Simulation, and Technology

,

WOBURN, Mass.–(BUSINESS WIRE)–Lincoln Memorial University (LMU) and Ethos Veterinary Health (Ethos) have entered into a unique collaborative relationship to advance their shared commitment to improve the profession through innovation in education. The relationship aims to transform learning in the veterinary community by leveraging Ethos’ unique commitment to learning and development and its online learning platform, VetBloom, and the strength of LMU’s pioneering educational model.

The multi-faceted partnership will allow for:

  • shared research on educational outcomes
  • advancing the use of simulations in clinical education
  • new ways of incorporating technology into training and continuous development

One component of the relationship consists of Ethos clinicians conducting virtual, case-based rounds with LMU students, providing them this type of learning very early in their education. “These rounds allow the LMU students to gain proficiency in clinical reasoning through case discussions,” said Linda Fineman, DVM, DACVIM (Oncology), Vice President of Learning and Development at Ethos. “At the same time, having the opportunity to give back to the next generation of veterinarians is rewarding for our clinicians.”

The partnership will capitalize on LMU’s educational expertise. LMU has a vast amount of experience and research building patient models through LMU’s Center for Innovation in Veterinary Education and Technology (CIVET). VetBloom currently has a unique anesthesia simulation and one area of mutual interest is in creating additional online simulations to expand their offerings. LMU and VetBloom share a goal of reaching underserved communities. Whether through VetBloom’s international reach, or LMU’s mission to serve the extensive Appalachian community, both organizations are focused on bringing advanced educational opportunities wherever they are needed.

“We’re very excited about this collaboration,” said John Weale, DVM, MS, Associate Dean, Clinical Relations and Outreach at LMU. “Not only does this benefit the teams at LMU and Ethos, but also the veterinary community at large.”

“This partnership is a living manifestation of our mutual commitment to advance veterinary learning by leveraging robust partnerships, rich technology, and succinct learning outcomes. It is, indeed, the future of education,” said Vice President and Dean of LMU-CVM, Dr. Jason Johnson.

The relationship promises to be fertile ground for ongoing exploration, and expansion of innovative programs.

About Lincoln Memorial University

Lincoln Memorial University is a non-profit, private, values-based learning community dedicated to providing educational experiences in the liberal arts and professional studies. The LMU-College of Veterinary Medicine is located on LMU’s main campus in Harrogate, Tennessee, with additional academic facilities in nearby Lee County, Virginia. LMU-CVM is an integral part of the University’s medical programs and provides real-world, community-based education in a collaborative learning environment. For more information visit vetmed.LMUnet.edu.

About Ethos Veterinary Health

Ethos is a veterinary health company with locations across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members, and collaboration. For more information visit ethosvet.com.

CNA Diagnostics and Ethos Veterinary Health Enter Strategic Partnership to Develop Suite of Diagnostic Tests for the Companion Animal Market

,

CNA Diagnostics Inc. (“CNAD”) and Ethos Veterinary Health (“Ethos”) are pleased to announce the parties have entered a strategic partnership to develop and distribute a suite of molecular diagnostic tests specifically designed to serve the companion animal market.

Read more…

VetDC Announces New TANOVEA®-CA1 Publication and State of the Art Presentation at the Veterinary Cancer Society 2017 Annual Conference

,

FORT COLLINS, Colo.–(BUSINESS WIRE)–VetDC, Inc., the leading veterinary cancer therapeutics company, today announced a new TANOVEA®-CA1 (rabacfosadine for injection) publication in Veterinary & Comparative Oncology. Data from this publication and several new VetDC-sponsored studies was prominently featured in a State of the Art presentation at the Veterinary Cancer Society (VCS) Annual Conference this past weekend in Portland, Oregon, with nearly 700 veterinary healthcare professionals in attendance.

Read more…

Ethos Veterinary Health Adds 15th Hospital: Vista Veterinary Specialists

,

Ethos Continues to Grow by Adding Select Practices

DENVER–(BUSINESS WIRE)–Vista Veterinary Specialists (Vista), a 24-hour specialty and emergency hospital located in Sacramento, Calif., joined Ethos Veterinary Health (Ethos) on August 2nd.

Vista is the 15th hospital owned and operated by Ethos. “Having Vista onboard adds to our growing set of veterinary hospitals and we are pleased to expand our presence in California,” said Ames Prentiss, CEO of Ethos.

For Ethos, partnering with hospitals that share its values, goals and commitment to innovation is paramount. Opportunities for growth and advancement of veterinary medicine, as well as individual growth, were of utmost importance for JT Vida, DVM, DACVS, owner of Vista. “When first contacted by Ethos, I was intrigued by the approach they are taking, which is very distinct from other veterinary groups,” said Dr. Vida. “Their concern for the individual coupled with a desire for the advancement of veterinary medicine really resonated with me. As discussions continued, it became apparent that Ethos could help Vista achieve so much more than we could by ourselves.”

Adding hospitals through mergers and acquisitions is part of Ethos’ long-term growth strategy. Having secured additional capital through a debt syndication, Ethos is looking to expand its hospital presence in current markets as well as new markets. “We are being selective and are in discussions with only those practices that best fit with Ethos – financially, geographically and culturally,” said Prentiss.

About Ethos Veterinary Health

Ethos Veterinary Health operates specialty and emergency veterinary hospitals with 15 locations cross the U.S. Ethos’ focus on team culture, professional growth of team members and scientific innovation leads to more fulfilled medical teams and improved care of patients and clients. For more information, visit ethosvet.com.

About Vista Veterinary Specialists

Vista Veterinary Specialists is a 24-hour emergency and referral practice in Sacramento, Calif., providing specialized and emergency care for companion animals. For more information, visit vistavets.com.